Incyte (INCY)
(Delayed Data from NSDQ)
$75.59 USD
+0.70 (0.93%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $75.60 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INCY 75.59 +0.70(0.93%)
Will INCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INCY
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Why Incyte (INCY) is a Top Value Stock for the Long-Term
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings
INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte (INCY) Reports Q2 Earnings: What Key Metrics Have to Say
Other News for INCY
Incyte (INCY) Leads Healthcare Gains Despite Market Dip
Notable healthcare headlines for the week: Trump’s ultimatum to big pharma, Novo Nordisk, UnitedHealth and Moderna in focus
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday
Avis Budget downgraded, Sprouts upgraded: Wall Street's top analyst calls
Barclays Initiates Coverage on INCY with Overweight Rating and $90 Price Target | INCY Stock News